Previous Close | 2.2350 |
Open | 2.2800 |
Bid | 2.2100 x N/A |
Ask | 0.0000 x N/A |
Day's Range | 2.2800 - 2.4400 |
52 Week Range | 0.6300 - 2.8000 |
Volume | |
Avg. Volume | 2,494 |
Market Cap | 163.526M |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3200 |
Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and a
Copperleaf Technologies Inc. (T.CPLF) hit a new 52-week high of $11.87 Tuesday. IFS, the leading technology ...
Cardiol Therapeutics Inc. (T.CRDL) hit a new 52-week high of $3.61 Tuesday. No news stories available ...